Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.

Abstract

This study was designed to assess the efficacy and safety of gemcitabine, cisplatin and methylprednisolone (GEM-P) for patients with relapsed or refractory Hodgkin's disease (HD) and non-Hodgkin's lymphoma. Twenty-one patients were treated with gemcitabine (1000 mg/m2 d 1, 8 and 15), cisplatin (100 mg/m2 d 15) and methylprednisolone (1000 mg d 1-5) given every 28 d. Of these, 20 patients were evaluable for response. The median age was 38 years (range 17-64 years). Histological subtypes were: nodular sclerosing HD (n = 10), diffuse large B cell (n = 5), T cell-rich B cell (n = 2), follicular (n = 2), mantle cell (n = 1) and enteropathy-associated T-cell lymphoma (n = 1). The median remission duration prior to receiving GEM-P was only 42 d. The overall objective response rate was 80%[95% confidence interval (CI): 56-94%], including five complete and 11 partial responses. GEM-P induced responses in all histological subtypes, primary progressive disease and patients who had received a previous autograft. The only grade 3-4 toxicity was myelosuppression. However, no cases of febrile neutropenia or haemorrhage with thrombocytopenia were encountered. Median survival has not yet been reached and survival probability at 1 year was 60.8% (95% CI: 31.9-80.5%). In conclusion, GEM-P is a novel combination salvage therapy for poor-prognostic primary progressive or multiply relapsed lymphoma patients. It has clinically significant activity with a favourable toxicity profile.

• Authors: Ian Chau, Mark Harries, David Cunningham, Mark Hill, Paul J Ross, Caroline D Archer, Andrew R Norman, Andrew Wotherspoon, Dow Mu Koh, Kairen Gill, Maggie Uzzell, Yvonne Prior, Daniel Catovsky
• Journal: British journal of haematology (Br J Haematol) Vol. 120 Issue 6 Pg. 970-7 (Mar 2003) ISSN: 0007-1048 [Print] England
• PMID: 12648066 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Deoxycytidine
• Cisplatin
• Methylprednisolone
• Gemcitabine

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cisplatin (administration & dosage)
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Disease-Free Survival
• Female
• Follow-Up Studies
• Hodgkin Disease (drug therapy, mortality)
• Humans
• Lymphoma (drug therapy, mortality)
• Lymphoma, B-Cell (drug therapy, mortality)
• Lymphoma, Follicular (drug therapy, mortality)
• Lymphoma, Large B-Cell, Diffuse (drug therapy, mortality)
• Lymphoma, Mantle-Cell (drug therapy, mortality)
• Lymphoma, T-Cell (drug therapy, mortality)
• Male
• Methylprednisolone (administration & dosage)
• Middle Aged
• Recurrence
• Survival Rate
• Gemcitabine